Pub Date : 2018-06-13DOI: 10.4172/1948-5956-C4-132
B. Zutshi, Nazima Noor
{"title":"Erythrocyte abnormalities in freshwater fish, Labeo rohita exposed to pollutants in lakes of Bangalore, India","authors":"B. Zutshi, Nazima Noor","doi":"10.4172/1948-5956-C4-132","DOIUrl":"https://doi.org/10.4172/1948-5956-C4-132","url":null,"abstract":"","PeriodicalId":15170,"journal":{"name":"Journal of Cancer Science & Therapy","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82096439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-06-13DOI: 10.4172/1948-5956-C4-133
N. Zaitseva, T. Ulanova, O. Dolgikh, O. V. Nurislamova, O. Maltseva, I. Alikina
{"title":"Early immune state violations in children associated with low concentrations of N-nitrosamines in blood","authors":"N. Zaitseva, T. Ulanova, O. Dolgikh, O. V. Nurislamova, O. Maltseva, I. Alikina","doi":"10.4172/1948-5956-C4-133","DOIUrl":"https://doi.org/10.4172/1948-5956-C4-133","url":null,"abstract":"","PeriodicalId":15170,"journal":{"name":"Journal of Cancer Science & Therapy","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73078410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-06-13DOI: 10.4172/1948-5956-C4-131
R. Robetorye
{"title":"Acute myeloid leukemia with characteristic molecular mutations","authors":"R. Robetorye","doi":"10.4172/1948-5956-C4-131","DOIUrl":"https://doi.org/10.4172/1948-5956-C4-131","url":null,"abstract":"","PeriodicalId":15170,"journal":{"name":"Journal of Cancer Science & Therapy","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89665058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-05-16DOI: 10.4172/1948-5956-C2-125
H. Brauch
{"title":"Endocrine treatment of breast cancer: current concepts to predict and prevent relapse","authors":"H. Brauch","doi":"10.4172/1948-5956-C2-125","DOIUrl":"https://doi.org/10.4172/1948-5956-C2-125","url":null,"abstract":"","PeriodicalId":15170,"journal":{"name":"Journal of Cancer Science & Therapy","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75087471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-05-16DOI: 10.4172/1948-5956.1000529
L. Graziosi, E. Marino, A. Donini
Introduction: Although gastric cancer incidence has decreased worldwide, it’ s still the fifth most frequent malignancy and the third leading cause of cancer related mortality. Many prognostic factors have been identified as indicators of gastric cancer prognosis including tumour size, depth, lymph nodes metastasis and microvascular involvement. To date the clinical significance of tumoral markers remains unclear. In our study we would like to investigate the prognostic survival significance of preoperative CEA and CA19.9.Material and Methods: From January 2004 to September 2016, a total of 326 gastric cancer patients were analysed. Of these 260 were enrolled in the study. The two serum tumour markers CEA and CA19.9 were detected within 7 days before surgery. The normal cut off value for serum CEA was 5 ng/ml whereas for CA19.9 was 35 U/ ml. Patients were also dichotomized according to CEA and CA19.9 median value (respectively 2 ng/ml and 9 U/ml).Results: Our results suggest that the optimal application of these common tumour markers could promote the clinical screening and staging of gastric cancer patients. Their evaluation is cheap and easy, allowing a routinely use to identify patients at high risk of death or post-surgical recurrences. Also, we could utilize the optimal cut-off value of CA19.9 for individualizing patients with an early stage but a very bad prognosis.Discussion and Conclusion: We conclude that the combined assessment of CA19.9 and CEA levels could have prognostic value in gastric cancer in particular to identify patients with a poor prognosis after radical surgery, who need an aggressive follow-up and medical treatment.
{"title":"Prognostic Value of CEA and Ca 19.9/Tumor Markers in Gastric Cancer to Identify Patients with Poor Prognosis after Radical Surgery","authors":"L. Graziosi, E. Marino, A. Donini","doi":"10.4172/1948-5956.1000529","DOIUrl":"https://doi.org/10.4172/1948-5956.1000529","url":null,"abstract":"Introduction: Although gastric cancer incidence has decreased worldwide, it’ s still the fifth most frequent malignancy and the third leading cause of cancer related mortality. Many prognostic factors have been identified as indicators of gastric cancer prognosis including tumour size, depth, lymph nodes metastasis and microvascular involvement. To date the clinical significance of tumoral markers remains unclear. In our study we would like to investigate the prognostic survival significance of preoperative CEA and CA19.9.Material and Methods: From January 2004 to September 2016, a total of 326 gastric cancer patients were analysed. Of these 260 were enrolled in the study. The two serum tumour markers CEA and CA19.9 were detected within 7 days before surgery. The normal cut off value for serum CEA was 5 ng/ml whereas for CA19.9 was 35 U/ ml. Patients were also dichotomized according to CEA and CA19.9 median value (respectively 2 ng/ml and 9 U/ml).Results: Our results suggest that the optimal application of these common tumour markers could promote the clinical screening and staging of gastric cancer patients. Their evaluation is cheap and easy, allowing a routinely use to identify patients at high risk of death or post-surgical recurrences. Also, we could utilize the optimal cut-off value of CA19.9 for individualizing patients with an early stage but a very bad prognosis.Discussion and Conclusion: We conclude that the combined assessment of CA19.9 and CEA levels could have prognostic value in gastric cancer in particular to identify patients with a poor prognosis after radical surgery, who need an aggressive follow-up and medical treatment.","PeriodicalId":15170,"journal":{"name":"Journal of Cancer Science & Therapy","volume":"117 4 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2018-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88525224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-05-04DOI: 10.4172/1948-5956.1000526
Nawal A. Al-Hamadi, Imad Al-Sabri, Amina B Aldujele, S. J. Al-fatlawi, Zuhair Allebban
Objective: To determine whether valsartan would be useful in attenuating Adriamycin/Cyclophosphamide/ Herceptin (ACH)-induced cardiotoxicity and to assess the role of biomarkers as indicators of cardiotoxicity in patients with breast cancer undergoing cancer therapy.Background: Valsartan is indicated to reduce the risk of cardiovascular death and hospitalization in patients with chronic heart disease. The administration of cancer drugs, in particular (ACH) is associated with increased risk of cardiotoxicity. The use of herceptin improves survival of women with early-stage positive human epidermal growth factor receptor 2 (HER2) breast cancer but also adds substantially to cost, toxicity, and inconvenience. Little is known about the potential role of valsartan in the prevention of ACH-mediated cardiotoxicity and the predictive role of biomarkers.Method: A total of 60 untreated HER-2 positive breast cancer patients (ages 24 –70 yr, mean 56 yr) were enrolled in this study and were divided to two groups. Group 1 and 2 had 30 patients each, and group 1 received ACH plus valsartan, group 2 received ACH alone. HER2- positive patients were recruited at the Cancer Therapy Center in Najaf, Iraq. Ejection fraction % (EF%), cardiac Troponin I (cTnI) and high sensitivity C-reactive protein (hsCRP) were measured at baseline and at six months after ACH administration.Results: Chemotherapy induced significant transient increase in EF%, cTnI, and hsCRP compared to baseline values (P < 0.001). Within one week after valsartan treatment, all these increases returned back to nearly normal levels. Notably, valsartan administration caused a significant decrease in cTnI and hsCRP values compared to baseline (P < 0.001) and it improved EF% value.Conclusion: This study demonstrated that prophylactic administration of valsartan resulted in the partial attenuation of cardiotoxicity caused by chemotherapy which was characterized by the improvement of EF% and in lowering serum level of cTnI and hsCRP.
{"title":"Valsartan Attenuates Cardiotoxicity in Breast Cancer Patients A fter Chemotherapy","authors":"Nawal A. Al-Hamadi, Imad Al-Sabri, Amina B Aldujele, S. J. Al-fatlawi, Zuhair Allebban","doi":"10.4172/1948-5956.1000526","DOIUrl":"https://doi.org/10.4172/1948-5956.1000526","url":null,"abstract":"Objective: To determine whether valsartan would be useful in attenuating Adriamycin/Cyclophosphamide/ Herceptin (ACH)-induced cardiotoxicity and to assess the role of biomarkers as indicators of cardiotoxicity in patients with breast cancer undergoing cancer therapy.Background: Valsartan is indicated to reduce the risk of cardiovascular death and hospitalization in patients with chronic heart disease. The administration of cancer drugs, in particular (ACH) is associated with increased risk of cardiotoxicity. The use of herceptin improves survival of women with early-stage positive human epidermal growth factor receptor 2 (HER2) breast cancer but also adds substantially to cost, toxicity, and inconvenience. Little is known about the potential role of valsartan in the prevention of ACH-mediated cardiotoxicity and the predictive role of biomarkers.Method: A total of 60 untreated HER-2 positive breast cancer patients (ages 24 –70 yr, mean 56 yr) were enrolled in this study and were divided to two groups. Group 1 and 2 had 30 patients each, and group 1 received ACH plus valsartan, group 2 received ACH alone. HER2- positive patients were recruited at the Cancer Therapy Center in Najaf, Iraq. Ejection fraction % (EF%), cardiac Troponin I (cTnI) and high sensitivity C-reactive protein (hsCRP) were measured at baseline and at six months after ACH administration.Results: Chemotherapy induced significant transient increase in EF%, cTnI, and hsCRP compared to baseline values (P < 0.001). Within one week after valsartan treatment, all these increases returned back to nearly normal levels. Notably, valsartan administration caused a significant decrease in cTnI and hsCRP values compared to baseline (P < 0.001) and it improved EF% value.Conclusion: This study demonstrated that prophylactic administration of valsartan resulted in the partial attenuation of cardiotoxicity caused by chemotherapy which was characterized by the improvement of EF% and in lowering serum level of cTnI and hsCRP.","PeriodicalId":15170,"journal":{"name":"Journal of Cancer Science & Therapy","volume":"10 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2018-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90442765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-04-07DOI: 10.4172/1948-5956.1000522
N. L. Lubis, H. Hasan
This research aims to identify the effect of Social Support (SS) intervention on the increase in the level of self-esteem and a decrease in the level of depression among cancer patients in Medan, Indonesia. The research that carried out is quantitative study. The quantitative study is applied to know the self-esteem scoring by Self- Esteem Rosenberg scale (RSE) and to know the depression score using Beck Depression Inventory scale (BDI). A quantitative analysis uses to know the interaction between intervention toward self-esteem and depression in groups. The groups consist of two groups: 10 people in SS group and eight people in Control group. T-test dependent results showed that the Self Esteem Rosenberg scale (RSE), on average, post-test score show greater self-esteem than pre-test score. Negative t value indicates that the average self-esteem of participants is lower than their self-esteem after obtaining social support interventions. This study shows that social support interventions significantly influence cancer patients to improve self-esteem and lower levels of depression. Although both have a significant influence to cancer patients, it turns out in this study social support interventions are much more effective in reducing levels of depression than by raising the self-esteem of participants.
{"title":"Intervention Social Support on Patients of CA. Cervix at Vina Estetika Hospital Medan","authors":"N. L. Lubis, H. Hasan","doi":"10.4172/1948-5956.1000522","DOIUrl":"https://doi.org/10.4172/1948-5956.1000522","url":null,"abstract":"This research aims to identify the effect of Social Support (SS) intervention on the increase in the level of self-esteem and a decrease in the level of depression among cancer patients in Medan, Indonesia. The research that carried out is quantitative study. The quantitative study is applied to know the self-esteem scoring by Self- Esteem Rosenberg scale (RSE) and to know the depression score using Beck Depression Inventory scale (BDI). A quantitative analysis uses to know the interaction between intervention toward self-esteem and depression in groups. The groups consist of two groups: 10 people in SS group and eight people in Control group. T-test dependent results showed that the Self Esteem Rosenberg scale (RSE), on average, post-test score show greater self-esteem than pre-test score. Negative t value indicates that the average self-esteem of participants is lower than their self-esteem after obtaining social support interventions. This study shows that social support interventions significantly influence cancer patients to improve self-esteem and lower levels of depression. Although both have a significant influence to cancer patients, it turns out in this study social support interventions are much more effective in reducing levels of depression than by raising the self-esteem of participants.","PeriodicalId":15170,"journal":{"name":"Journal of Cancer Science & Therapy","volume":"30 1","pages":"76-79"},"PeriodicalIF":0.0,"publicationDate":"2018-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86640657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-03-28DOI: 10.4172/1948-5956.1000519
D. Gupta, V. Singh
Purpose: To study and assess to the sensitivity of Burkitt’s lymphoma cells harboring differential levels of cell surface CD20 for anti-CD20 monoclonal Antibodies. Material and methods: Burkitt’s lymphoma cell line ‘Daudi’ was used during present study. Cells were exposed to single dose of γ-radiation (0.5 Gy) and thereafter incubated with rituximab (Rtx) or tositumomab (Tst) (0.5 μg/ ml concentration each). The changes in expression of RelA, Akt and Bax/Bcl-2 ratio was measured to assess sensitivity of cells in term of cell death. Results: During the present investigation, we found that cells incubated with anti-CD20 mAbs at +20 hrs post radiation exposure showed higher levels of cell death in term of Bax/Bcl-2 ratio. In addition, we also found the significant changes in expression of pro-survival signaling proteins such as RelA and Akt pathways. Moreover, we found that tositumomab is a potent inducer of apoptotic cell death. Conclusion: These findings suggested that the efficacy of anti-CD20 mAbs depends on the number of CD20 molecules expressed on cell surface and type of antibody used. It may provide new treatment options for selection of anti-CD20 mAbs even in aggressive B-cell lymphoma, which harbors low levels of CD20 or even resistant to current therapies in vivo.
{"title":"Differential Action of Anti-CD20 Monoclonal Antibodies: Role in Induction of Cell Death","authors":"D. Gupta, V. Singh","doi":"10.4172/1948-5956.1000519","DOIUrl":"https://doi.org/10.4172/1948-5956.1000519","url":null,"abstract":"Purpose: To study and assess to the sensitivity of Burkitt’s lymphoma cells harboring differential levels of cell surface CD20 for anti-CD20 monoclonal Antibodies. Material and methods: Burkitt’s lymphoma cell line ‘Daudi’ was used during present study. Cells were exposed to single dose of γ-radiation (0.5 Gy) and thereafter incubated with rituximab (Rtx) or tositumomab (Tst) (0.5 μg/ ml concentration each). The changes in expression of RelA, Akt and Bax/Bcl-2 ratio was measured to assess sensitivity of cells in term of cell death. Results: During the present investigation, we found that cells incubated with anti-CD20 mAbs at +20 hrs post radiation exposure showed higher levels of cell death in term of Bax/Bcl-2 ratio. In addition, we also found the significant changes in expression of pro-survival signaling proteins such as RelA and Akt pathways. Moreover, we found that tositumomab is a potent inducer of apoptotic cell death. Conclusion: These findings suggested that the efficacy of anti-CD20 mAbs depends on the number of CD20 molecules expressed on cell surface and type of antibody used. It may provide new treatment options for selection of anti-CD20 mAbs even in aggressive B-cell lymphoma, which harbors low levels of CD20 or even resistant to current therapies in vivo.","PeriodicalId":15170,"journal":{"name":"Journal of Cancer Science & Therapy","volume":"19 1","pages":"64-68"},"PeriodicalIF":0.0,"publicationDate":"2018-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81604560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-03-24DOI: 10.4172/1948-5956-C3-129
H. B. Dominguez
E Transition (EMT) is a phenotype conversion that plays a critical role in the development of cancer progression. It is known that snail could regulate the progression of EMT. Nuclear factor erythroid 2 related factor 2 (NRF2), a key regulator of antioxidant defense system, protects cells against oxidative stress. We discovered overexpression of NRF2 is poor prognosis in human ovarian cancer patient’s tissue section by tissue microarray. In this study, expression of NRF2 in A2780, TOV-21G, TOV-112D and ES-2 human ovarian cancer cell lines and virus transformed human ovarian cell line A2780 was examined by qPCR and western blot. NRF2 expression was further studied in A2780 and transfection cell lines. By Western blot analysis, the performance of the NRF2 and snail is consistent in shNRF2 of A2780 cell lines. Down-regulation of NRF2 could increase cisplatin sensitivity and decrease cell migration and invasion. Therefore, we suggested NRF2 attenuates EMT by regulating the expression of snail in ovarian cancer.
{"title":"Merkel cell carcinoma in an 82-year-old Filipino male: A case report and literature review","authors":"H. B. Dominguez","doi":"10.4172/1948-5956-C3-129","DOIUrl":"https://doi.org/10.4172/1948-5956-C3-129","url":null,"abstract":"E Transition (EMT) is a phenotype conversion that plays a critical role in the development of cancer progression. It is known that snail could regulate the progression of EMT. Nuclear factor erythroid 2 related factor 2 (NRF2), a key regulator of antioxidant defense system, protects cells against oxidative stress. We discovered overexpression of NRF2 is poor prognosis in human ovarian cancer patient’s tissue section by tissue microarray. In this study, expression of NRF2 in A2780, TOV-21G, TOV-112D and ES-2 human ovarian cancer cell lines and virus transformed human ovarian cell line A2780 was examined by qPCR and western blot. NRF2 expression was further studied in A2780 and transfection cell lines. By Western blot analysis, the performance of the NRF2 and snail is consistent in shNRF2 of A2780 cell lines. Down-regulation of NRF2 could increase cisplatin sensitivity and decrease cell migration and invasion. Therefore, we suggested NRF2 attenuates EMT by regulating the expression of snail in ovarian cancer.","PeriodicalId":15170,"journal":{"name":"Journal of Cancer Science & Therapy","volume":"103 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79455851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-02-15DOI: 10.4172/1948-5956.1000513
A. Nagy, Hosam Darweish, H. Elkalla, Heba Abdu-allah, L. Ahmed, E. Salah, R. Haggag
Background: Bladder cancer is the second most common malignancy among Egyptian males. Patients and methods: To investigate the factors affecting survival in Egyptian patients suffering from urinary bladder cancer, we analyzed the geographical patterns of 564 bladder cancers patients from Oncology Departments of Ain Shams University, Mansoura University, Zagazig University and Damietta oncology centerover a period of 7 years between January 2006 and September 2013. Results: Among the included 564 patients, Males represented 72.5% of the patients. While, 27.5% were female with a male to female ratio of 2.6, 227 patients presented with non-metastatic and 337 patients with metastatic urinary bladder cancer. Grade III was found in 36% of our patients and 60% of them had stage IV. Mean DFS was (9.15 ± 0.5) and (4.4 ± 0.1) while, mean OS was (13.5 ± 0.7) and (7.5 ± 0.15) months for non-metastatic, and metastatic patients, respectively. In univariate analysis, patients with no bilharzial infection, Non-SCC, responding patients had significant better DFS and OS vs. patients with bilharzial infection, SCC, non-responding patients (respectively, p=0.001 for all). In multivariate analysis, response (OS and PFS), SCC (OS and PFS) and bilharzias is (OS and PFS) where found to be highly statistically significant (Cox regression, P<0.001 for all) in the metastatic and non-metastatic group of patients. Conclusion: Non-responding, SCC type and bilharzial infected patients had significant independent poor prognostic factors for OS and PFS in the metastatic and non-metastatic group of patients.
{"title":"Factors Affecting Survival in Egyptian Patients Suffering from Urinary Bladder Cancer: A Multicenter Retrospective Study","authors":"A. Nagy, Hosam Darweish, H. Elkalla, Heba Abdu-allah, L. Ahmed, E. Salah, R. Haggag","doi":"10.4172/1948-5956.1000513","DOIUrl":"https://doi.org/10.4172/1948-5956.1000513","url":null,"abstract":"Background: Bladder cancer is the second most common malignancy among Egyptian males. \u0000Patients and methods: To investigate the factors affecting survival in Egyptian patients suffering from urinary bladder cancer, we analyzed the geographical patterns of 564 bladder cancers patients from Oncology Departments of Ain Shams University, Mansoura University, Zagazig University and Damietta oncology centerover a period of 7 years between January 2006 and September 2013. \u0000Results: Among the included 564 patients, Males represented 72.5% of the patients. While, 27.5% were female with a male to female ratio of 2.6, 227 patients presented with non-metastatic and 337 patients with metastatic urinary bladder cancer. Grade III was found in 36% of our patients and 60% of them had stage IV. Mean DFS was (9.15 ± 0.5) and (4.4 ± 0.1) while, mean OS was (13.5 ± 0.7) and (7.5 ± 0.15) months for non-metastatic, and metastatic patients, respectively. In univariate analysis, patients with no bilharzial infection, Non-SCC, responding patients had significant better DFS and OS vs. patients with bilharzial infection, SCC, non-responding patients (respectively, p=0.001 for all). In multivariate analysis, response (OS and PFS), SCC (OS and PFS) and bilharzias is (OS and PFS) where found to be highly statistically significant (Cox regression, P<0.001 for all) in the metastatic and non-metastatic group of patients. \u0000Conclusion: Non-responding, SCC type and bilharzial infected patients had significant independent poor prognostic factors for OS and PFS in the metastatic and non-metastatic group of patients.","PeriodicalId":15170,"journal":{"name":"Journal of Cancer Science & Therapy","volume":"49 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2018-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79360980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：